ADMA vs BSX: fair value comparison
ADMA Biologics, Inc. and Boston Scientific Corporation · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BSX currently sits closer to the top of our ranking by discount to fair value.
| ADMA | BSX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $10.68 | $42.73 |
| 12-month range | $7.60–$20.38 | $41.58–$104.98 |
| Rank by discount to fair value | #97 of 108 Healthcare | #2 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ADMA fair value analysis · BSX fair value analysis